utrophin therapy

The drug SMT C1100 is still experimental, but an MDA-supported company has received two US patents that provide commercial protection for its development

posted on September 3, 2013 - 5:00am
Summit PLC, a biotechnology company based in Abingdon, United Kingdom, has announced it now has two U.S. patents for its experimental drug SMT C1100 for Duchenne muscular dystrophy (DMD).

New content is being added every day. Please check back again.